Market Intelligence, Business development, Launch Excellence, Reimbursement & Policy
Collaborating closely with leadership teams to provide strategic input on business development and marketing initiatives for both domestic and international markets
Generating business leads in areas such as drug discovery, reactions, and formulations
Closing business deals, including the sale of AI-driven drug molecules (internal molecules), as well as securing partnerships for the discovery and development of drug molecules aligned with client interests (external molecules) Promoting the client's comprehensive AI capabilities in drug discovery, chemistry, and flow chemistry Creation and marketing of the client's brand and business model across both domestic and global markets
Shaping the client's peri-launch strategy, with a particular emphasis on marketing, pricing & reimbursement

Hematology & Biosimilars
Provide analytical and technical support to country access teams, shaping pricing and contracting strategies for a portfolio worth USD 200M. Building high performing teams and be a thought partner for business transformation/creation. Formulated winning access strategies including Managed Entry Agreements for a 200M$ portfolio. Securing superior reimbursement within twelve months of launch and three-year consecutive tender wins for Biosimilar portfolio, outperforming industry standards.
Led the development of innovative patient access/support programs and introduced Temporary Alternate Access Mechanisms, addressing affordability challenges, and accelerating market penetration in self-pay segments by 25%.
Designed an agile process and framework for swift evaluation of all pipeline assets and aligning seamlessly with regional management team on forecasts and peri launch plans. Initiated a strategic access expansion project, diversifying our portfolio and craft

Set regional priorities and craft access strategies, including ecosystem shaping, to secure successful reimbursement listings and broaden access across public and private sectors. Secured a competitive advantage with an insights-driven reimbursement strategy, outpacing competitors by up to two years across AU, KR, TW, & CN for a launch brand worth 150M$. Accelerated in-country reimbursement, enabling submission within a quarter post-commercialization. Led 18plus HE studies, securing initial reimbursement and broadening access across 8 affiliates.
Advised and supported writing of one PBSC, HIRA, NHIS, NRDL and two ACE submissions that have been approved. Steered impactful external engagement in advocacy and policy shaping within CV and Bone domains. Led the planning and execution of an innovative economic model (FESI) to elevate the importance of lipid management across different stakeholder groups. As Brand Team Lead, spearheaded cross-functional collaboration by developing the 360⁰ C

Responsible for the re-integration of Amgen brands from GSK & Roche, elevating existing brand strategies through the development of a pan-Asia approach during affiliate growth. Spearheaded and implemented efficient processes and systems for upcoming 80 plus product launches.
Expanded the market with the "Amplify Osteoporosis" initiative, seizing 70% share in AU and achieving leadership across key affiliates in just two years for a 600M$ portfolio. As Brand Team Lead, crafted data-driven strategies that surpassed KPIs achieving 90% plus market dominance in Japan and market leadership in other affiliates.
With limited launch experience across the organization, designed and implemented the Launch Excellence initiative including Brand Planning process, transforming governance, strategy, and talent levers.
Collaborated with Medical teams to establish a differentiation workstream focused on Value-Based Partnership pilot projects, transitioning from a Break it Fix it to a Predict & Prevent

Accountable for revitalizing a non-performing business unit worth Euros 200M and overseeing peri-launch planning of a novel product worth Euros 150M, including formalizing team structures, membership, and responsibilities to lead and participate in launch readiness at both regional and affiliate levels.
Guided a strategic overhaul, turning around a declining Primary Care portfolio worth 200M Euros which was contributing to over 25% of regional turnover within 15 months.
Delivered strategic direction to rejuvenate mature brands and evaluate BD opportunities, leading to the successful launch of three new line extensions in Asia and initiating evaluations for four global extensions.
Directed a pre-launch team, crafting a strategy that boosted molecule awareness quarter-over-quarter for two years leading up to launch, ensuring market, product, and organizational readiness.
As Launch Lead, sharpened regional and country strategies, slashing launch timelines by 8-12 months and securing r

Managed a portfolio worth 310 mio Euros, with all 3 brands outpacing market growth

Created a Specialty Division to enhance the CV portfolio (Lipobay) & enter the Biological segment. Overcame complexity of market situation by setting-up the sales structure & distributions channel, Defining road map for the Specialty Division, Commercial role with respect to pricing & contract negotiations with Distribution partners.

Spearheaded indication expansion for our biggest asset, Glucobay by getting an approval in IGT. The indication was approved by MoH in record time despite non-availability of US FDA / UK MHRA approval – a prerequisite for any approval in India

Build Export business in Nepal, Sri Lanka. Partnered with local distributors in Nepal and Sri Lanka for developing an optimum cost model to generate a profitable business and to provide strategic support to maintain sales.

Developed marketing campaigns & tactical plans for vitamins/cardiology & derma range of products